MDGL - Bull Thesis

BULL THESIS

• MDGL overall corporate and executive summary

  • Pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver

  • Cash thru key upcoming readouts and into early 2023

  • Lead candidate resmetirom for NASH has yielded promising late-stage clinical data

    • Recent Ph3 data in NAFLD provides more confidence for huge Q4 2022 Ph3 NASH readout

    • Several positive Ph2/3 liver disease trials that have shown robust improvements in lipid parameters that could eventually yield cardio risk-reduction success.

  • High unmet need - indication (NASH), with huge potential upside.

  • One of the frontrunners for possible approval in NASH

    • At least 1 yr ahead of VKTX therapeutic with same MOA

• Resmetirom (MGL-3196) (THR-B Agonist)(NAFLD)

  • First-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist.

  • 1/31/22 Positive Phase 3 MAESTRO-NAFLD-1 results. “MRI-PDFF reductions were robust, with nearly half of patients in the resmetirom 100 mg arm achieving a 50% PDFF reduction” (source)

    • Primary safety endpoints met

    • 969 patient trial compared to VKTX 31 patients

    • MRI-PDFF %CFB (Week 16) -49% -53% (week 52)

    • LDLc %CFB (SE) (Week 24) -21

  • Stock increase from (~$57.58 (1/31/22) to ~$90.41(2/9/22)

    • Positive data gives more confidence for pivotal MAESTRO NASH catalyst this year

• Resmetirom (MGL-3196) (THR-B Agonist)(NASH)

  • Potential to be the first approved candidate. Assuming competitor (ICPT) failure and $MDGL trial success this year.

  • Big Mover Event - Expect large price increase if trial is successful and/or running up to trial readout

  • Further in clinical development than competitor VK2809 (same MOA)

    • Over 1 year ahead of VKTX and probably years ahead of competition

  • Currently in MAESTRO NASH pivotal phase 3 trial, topline data due Q4 2022

    • (MRI-PDFF-MRE-AST) score to predict NASH on liver biopsyPositive Phase 2 results for NASH (source)

    • 60.3% Percentage of patients attained ≥30% liver fat reduction

    • -36.3% Relative change in MRI-PDFF (% change from baseline, median)

    • Safety data - some loose stool but overall looks good, consistent with lower dose phase 2 safety data. Safe at 100mg vs 80mg for phase 2 NASH.

JM/MV 3/10/22

See our updated bull, bear, Amp View forum post HERE after becoming a subscriber. Learn more here.